Synthetic mRNA for ex vivo therapeutic applications

Hideyuki Nakanishi; Keiji Itaka

doi:10.1016/j.dmpk.2022.100447

Synthetic mRNA for ex vivo therapeutic applications

Drug Metab Pharmacokinet. 2022 Jun:44:100447. doi: 10.1016/j.dmpk.2022.100447. Epub 2022 Jan 15.

Authors

Hideyuki Nakanishi¹, Keiji Itaka²

Affiliations

¹ Department of Biofunction Research, Institute of Biomaterials and Bioengineering, Tokyo Medical and Dental University (TMDU), 2-3-10 Kanda-Surugadai, Chiyoda-ku, Tokyo, 101-0062, Japan.
² Department of Biofunction Research, Institute of Biomaterials and Bioengineering, Tokyo Medical and Dental University (TMDU), 2-3-10 Kanda-Surugadai, Chiyoda-ku, Tokyo, 101-0062, Japan. Electronic address: itaka.bif@tmd.ac.jp.

PMID: 35286863
DOI: 10.1016/j.dmpk.2022.100447

Abstract

Synthetic mRNA is attracting much attention as a new drug modality. Now, there is great interest in the next applications of mRNA medicines, especially for therapeutic purposes of various diseases. Not only in vivo applicable mRNA medicines, there are many researches using ex vivo or in vitro mRNA transfection, some of which are already used in the preclinical or clinical settings. In this short article, the ex vivo mRNA applications are reviewed, in the hope of providing insight to develop future mRNA medicines.

Keywords: Cell engineering; Genome editing; Messenger RNA (mRNA); Reprogramming; mRNA medicine.

Publication types

Review

MeSH terms

RNA, Messenger* / genetics
Transfection

Substances

RNA, Messenger